Draft guidance for recurrent ovarian cancer
The National Institute for Health and Care Excellence (NICE) has published draft guidance that covers five drugs — paclitaxel, pegylated liposomal doxorubicin hydrochloride (PLDH), topotecan, trabectedin and gemcitabine — for treating recurrent ovarian cancer. The guidance recommends paclitaxel and PLDH for treating recurrent ovarian cancer but proposes not recommending gemcitabine, topotecan and trabectedin for treating the first recurrence of platinum-sensitive ovarian cancer (where the disease responds to first-line, platinum-based therapy but returns over six months after this treatment). The guidance is available for consultation from the NICE website until 15 December 2015.
Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20200186
Recommended from Pharmaceutical Press
Commonly known as the Orange Guide, this book is an essential reference for all involved in the manufacture or distribution of medicines in Europe.£82.00Buy now
Pharmacy Registration Assessment Questions 2 features more than 400 entirely new, closed book and calculation questions. It can be used in conjunction with the previous volume or on its own. All questions are in line with current GPhC guidance, enabling you to prepare for the pharmaceutical pre-registration exam with confidence.£35.00Buy now